Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 254 Shares

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 254 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $84.10, for a total value of $21,361.40. Following the completion of the transaction, the president now directly owns 1,442,357 shares in the company, valued at $121,302,223.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Stephen Hoge also recently made the following trade(s):

• On Monday, July 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $121.12, for a total transaction of $1,816,800.00.
• On Monday, June 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00.
• On Wednesday, May 29th, Stephen Hoge sold 341 shares of Moderna stock. The stock was sold at an average price of $144.50, for a total value of $49,274.50.

Moderna Stock Up 5.3 %

Shares of MRNA opened at $86.62 on Friday. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47. The firm has a market capitalization of $33.20 billion, a P/E ratio of -5.53 and a beta of 1.67. The company has a 50-day simple moving average of $117.52 and a 200-day simple moving average of $113.92. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.91 and a current ratio of 4.09.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm’s revenue for the quarter was down 29.9% compared to the same quarter last year. During the same period last year, the firm earned ($3.62) EPS. On average, equities research analysts expect that Moderna, Inc. will post -7.46 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MRNA. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and cut their price target for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. JPMorgan Chase & Co. dropped their price target on Moderna from $96.00 to $88.00 and set a “neutral” rating on the stock in a research report on Thursday. Barclays reduced their price target on Moderna from $168.00 to $155.00 and set an “overweight” rating for the company in a research report on Friday, August 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Thursday, August 1st. Finally, Evercore ISI reiterated an “in-line” rating and issued a $120.00 price target on shares of Moderna in a research report on Thursday, June 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and a consensus price target of $124.07.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Moderna by 22.6% in the fourth quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock valued at $3,372,058,000 after purchasing an additional 6,248,623 shares in the last quarter. Norges Bank acquired a new position in shares of Moderna during the fourth quarter valued at $347,565,000. Wellington Management Group LLP boosted its holdings in Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after acquiring an additional 1,614,460 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Moderna by 42.9% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock worth $164,724,000 after purchasing an additional 463,960 shares during the last quarter. Finally, Matrix Capital Management Company LP acquired a new position in Moderna during the 4th quarter valued at about $45,150,000. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.